Another study emphasized the active inhibitory role of HDAC and ERK signaling cascades in restricting MHC II expression in lung cancer cells, and suggested that the combinatorial blockade of these pathways may engender new responses to checkpoint therapies [29]. The gene discussed is HDAC9; the disease is lung cancer.